Prophylactic efficacy of 5-HT4R agonists against stress

Briana K. Chen, Indira Mendez-David, Victor M. Luna, Charlene Faye, Alain M. Gardier, Denis J. David, Christine A. Denny

Abstract: Enhancing stress resilience could protect against stress-induced psychiatric disorders in at-risk populations. We and others have previously reported that (R,S)-ketamine acts as a prophylactic against stress when administered 1 week before stress. While we have shown that the selective 5-hydroxytryptamine (5-HT) (serotonin) reuptake inhibitor (SSRI) fluoxetine (Flx) is ineffective as a prophylactic, we hypothesized that other serotonergic compounds such as serotonin 4 receptor (5-HT4R) agonists could act as prophylactics. We tested if three 5-HT4R agonists with varying affinity could protect against stress in two mouse strains by utilizing chronic corticosterone (CORT) administration or contextual fear conditioning (CFC). Mice were administered saline, (R,S)-ketamine, Flx, RS-67,333, prucalopride, or PF-04995274 at varying doses, and then 1 week later were subjected to chronic CORT or CFC. In C57BL/6N mice, chronic Flx administration attenuated CORT-induced weight changes and increased open-arm entries in the elevated plus maze (EPM). Chronic RS-67,333 administration attenuated CORT-mediated weight changes and protected against depressive- and anxiety-like behavior. In 129S6/SvEv mice, RS-67,333 attenuated learned fear in male, but not female mice. RS- 67,333 was ineffective against stress-induced depressive-like behavior in the forced swim test (FST), but prevented anxiety-like behavior in both sexes. Prucalopride and PF-04995274 attenuated learned fear and decreased stress-induced depressive-like behavior. Electrophysiological recordings following (R,S)-ketamine or prucalopride administration revealed that both drugs alter AMPA receptor-mediated synaptic transmission in CA3. These data show that in addition to (R,S)-ketamine, 5-HT4R agonists are also effective prophylactics against stress, suggesting that the 5-HT4R may be a novel target for prophylactic drug development.

Patents

Prophylactic efficacy of serotonin 4 receptor agonists against stress, PCT/US20/027321

RS67333 (1-(4-Amino-5-chloro-2-methoxyphenyl)-3-[1-butyl-4-piperidinyl]-1-propanone hydrochloride) as a prophylactic and anxiolytic compound, US62/831,517

Serotonin receptor type IV (5-HT4) agonists are prophylactic against stress-induced and anxiety-like behavior, US62/857,075

Prophylactic efficacy of 5-HT4R agonists against stress, US62/910,859

Funding

Synthetic design of a novel resilience-enhancing small molecule therapeutic targeting 5-HT4Rs, Columbia Translational Therapeutics Accelerator (TRx)

Previous
Previous

Ketamine and stereospecific metabolites

Next
Next

Fluoroethylnormemantine